CHICAGO / Mar 31, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the... Read More

IRVINE, Calif. / Feb 25, 2025 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45 th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/ , with an... Read More

IRVINE, Calif. / Feb 11, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion 1 , better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency 2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards'... Read More

IRVINE, Calif. / Feb 04, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on... Read More

NEW YORK / Dec 04, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth... Read More

LONDON / Nov 25, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. An analysis of data from more than 9,000 propensity-matched patients... Read More

WASHINGTON / Oct 30, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease. “The data at TCT on Edwards’ innovations underscore our commitment to scientific leadership and our focus to... Read More

WASHINGTON / Oct 30, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy... Read More

WASHINGTON / Oct 28, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe AS patients randomized to... Read More

IRVINE, Calif. / Oct 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency 1 sales grew 10% Q3 TAVR sales grew 6%; constant currency 1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted 1 EPS... Read More

IRVINE, Calif. / Oct 17, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived... Read More

NAPERVILLE, Ill. , Sept. 28, 2024 /PRNewswire/ -- Endotronix, an Edwards Lifesciences company (NYSE: EW), today announced the one-year clinical results from PROACTIVE-HF, evaluating outcomes for the Cordella Pulmonary Artery (PA) Sensor System. The data were shared as part of the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The data demonstrated that the 456 patients managed with Cordella in the study... Read More

Company announces $1 billion share repurchase IRVINE, Calif. / Sep 03, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX) for $4.2 billion in an all-cash transaction. The net proceeds from the sale will be used to fund strategic initiatives including the previously announced acquisitions and share... Read More

LONDON / Aug 31, 2024 / Business Wire / Please replace the release with the following corrected version. The updated release reads: FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI).... Read More

LONDON / Aug 31, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 Ultra or SAPIEN 3... Read More

IRVINE, Calif. / Aug 21, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations... Read More

IRVINE, Calif. / Jul 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology , a pioneer in the transcatheter treatment of aortic... Read More

IRVINE, Calif. / Jul 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency 1 sales grew 8% Q2 TAVR sales grew 5%; constant currency 1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted 1 EPS of $0.70 Significant TAVR and TMTT clinical... Read More

IRVINE, Calif. / Jul 17, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the... Read More

IRVINE, Calif. / Jul 15, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience. Combined with Edwards’ existing mitral... Read More

NEW YORK / Jun 05, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the... Read More

Agreement strengthens Edwards’ strategy to advance structural heart innovation IRVINE, CA / Jun 03, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously... Read More

IRVINE, Calif. / Apr 25, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency 1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted 1 EPS of $0.66 Raising 2024 sales guidance to... Read More

IRVINE, Calif. / Apr 18, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the... Read More

ATLANTA / Apr 07, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families. The findings of this study, which identified a significant discrepancy between participant self-awareness and actual prevalence of heart... Read More

WASHINGTON / Mar 11, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards’ latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower... Read More

IRVINE, Calif. / Feb 23, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations... Read More

IRVINE, Calif. / Feb 06, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency 1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted 1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of... Read More

IRVINE, Calif. / Feb 02, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system... Read More

IRVINE, Calif. / Jan 30, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on... Read More

IRVINE, Calif. / Jan 02, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards... Read More

SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as one-year results from the CLASP IID registry. The studies confirm the clinical and quality-of-life benefits of mitral regurgitation (MR) reduction... Read More

SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization. The outcomes for the first 150 patients of the... Read More

IRVINE, Calif. , Oct. 25, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook Q3 sales grew 12 percent to $1.48 billion ; constant currency 1 sales grew 11 percent Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent Q3 EPS of $0.63 ; adjusted 1 EPS of $0.59 Received CE Mark for EVOQUE, the first... Read More

SAN FRANCISCO , Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years. These data, which represent the longest clinical follow-up for a low surgical risk cohort of transcatheter aortic valve replacement (TAVR) patients, were presented during a late-breaking... Read More

IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR). The EVOQUE system is the world's first transcatheter valve... Read More

IRVINE, Calif. , Oct. 18, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, October 25, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived... Read More

IRVINE, Calif. , Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7 , 2023. Bernard Zovighian, chief executive officer, and Scott B. Ullem , chief financial officer, are scheduled to speak to conference attendees at 11:00 a.m. ET . A live webcast of the presentation will be available to all... Read More

IRVINE, Calif. , July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion ; constant currency 1 sales grew 12 percent All product groups achieved double digit constant currency sales growth in Q2 Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percent Q2 EPS of $0.50... Read More

IRVINE, Calif. , July 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday, July 26, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the... Read More

PARIS , May 17, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. The data were presented in a late-breaking clinical data session at EuroPCR 2023. The study observed 2,405... Read More

LOS ANGELES , May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, which represent the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7... Read More

IRVINE, Calif. , April 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023 . Highlights and Outlook Q1 sales grew 9 percent to $1.46 billion ; constant currency 1 sales grew 13 percent Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent Q1 EPS of $0.56 ; adjusted 1 EPS of $0.62 Repurchased approximately $250 million of Edwards stock... Read More

IRVINE, Calif. , April 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2023 after the market closes on Wednesday, April 26, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on... Read More

NEW ORLEANS , March 6, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data. Together these studies, presented at the American College of Cardiology ACC.23/WCC, add... Read More

IRVINE, Calif. , Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 , 2023. Michael A. Mussallem, chairman and chief executive officer, is scheduled to present at 11:15 a.m. PT . Bernard Zovighian, president and incoming chief executive officer, and Scott Ullem , chief financial officer, will also... Read More

IRVINE, Calif. , Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance 1 today during its annual investor conference. Highlights of today's conference include: Global market opportunity across 4 product groups projected to double to nearly $20 billion by 2028 Reaffirming... Read More

IRVINE, Calif. , Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem , who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023 . At the 2023 annual... Read More

LONDON , Nov. 27, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. The data were presented during the late-breaking trials session at PCR London... Read More